Cannabidiol in low back pain: scientific rationale for clinical trials in low back pain

References

• Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20(6):E755–E796.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Hitchcock SA. Targeting cannabinoid agonists for inflammatory and neuropathic pain. Expert Opin Investig Drugs. 2007;16(7):951–965.
   PubMed Web of Science ®Google Scholar
• Machado Bergamaschi M, Helena Costa Queiroz R, Waldo Zuardi A, et al. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011;6(4):237–249.
   PubMedGoogle Scholar
• Romero‐Sandoval EA, Fincham JE, Kolano AL, et al. Cannabis for chronic pain: challenges and considerations. Pharmacother J Human Pharmacol Drug Ther. 2018;38(6):651–662.
   Google Scholar
• Correa F, Docagne F, Mestre L, et al. A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem Pharmacol. 2009;77(1):86–100.
   PubMed Web of Science ®Google Scholar
• Moulin DE, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian pain society. Pain Res Manag. 2014;19(6):328–335.
   PubMed Web of Science ®Google Scholar
• Laprairie RB, Bagher AM, Kelly MEM, et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790–4805.
   PubMed Web of Science ®Google Scholar
• Espejo-Porras F, Fernández-Ruiz J, Pertwee RG, et al. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology. 2013;75:155–163.
   PubMed Web of Science ®Google Scholar
• Costa B, Giagnoni G, Franke C, et al. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol. 2004;143(2):247–250.
   PubMed Web of Science ®Google Scholar
• Baron EP, Lucas P, Eades J, et al. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain. 2018;19(1):1–28.
   PubMedGoogle Scholar
• Crippa JAS, Hallak JE, Zuardi AW. et al. Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms? Eur archives psychiatry clin neurosci. 2019;269(1):121–133.
   PubMed Web of Science ®Google Scholar
• Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159(10):1932–1954.
   PubMed Web of Science ®Google Scholar
• Sharpe L, Sinclair J, Kramer A, et al. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J Transl Med. 2020;18(1):1–21.
   PubMed Web of Science ®Google Scholar
• Jurkus R, Day HL, Guimarães FS, et al. Cannabidiol regulation of learned fear: implications for treating anxiety-related disorders. Front Pharmacol. 2016;7(454). DOI:10.3389/fphar.2016.00454.
   PubMedGoogle Scholar
• Morales P, Hurst DP, Reggio PH. Molecular Targets of the Phytocannabinoids: A Complex Picture. Prog Chem Org Nat Prod. 2017;103:103-131. doi: 10.1007/978-3-319-45541-9_4. PMID: 28120232; PMCID: PMC5345356.
   Google Scholar
• Morales P, Goya P, Jagerovic N, et al. Allosteric modulators of the CB1 cannabinoid receptor: a structural update review. Cannabis Cannabinoid Res. 2016;1(1):22–30.
   PubMedGoogle Scholar
• Rock EM, Bolognini D, Limebeer CL, et al. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol. 2012;165(8):2620–2634.
   PubMed Web of Science ®Google Scholar
• Russo EB, Burnett A, Hall B, et al. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037–1043.
   PubMed Web of Science ®Google Scholar
• Bitencourt RM, Takahashi RN. Cannabidiol as a therapeutic alternative for post-traumatic stress disorder: from bench research to confirmation in human trials. Front Neurosci. 2018;12(502):1-10.
   PubMedGoogle Scholar
• Papagianni EP, Stevenson CW. Cannabinoid regulation of fear and anxiety: an update. Curr Psychiatry Rep. 2019;21(6):1–10.
   PubMed Web of Science ®Google Scholar
• Kim J, Choi JY, Seo J, et al. Neuroprotective effect of cannabidiol against hydrogen peroxide in hippocampal neuron culture. Cannabis Cannabinoid Res. 2021;6(1):40–47.
   PubMedGoogle Scholar
• Tura M, Mandrioli M, Gallina Toschi T. Preliminary study: comparison of antioxidant activity of cannabidiol (CBD) and α-tocopherol added to refined olive and sunflower oils. Molecules. 2019;24(19):3485.
   Web of Science ®Google Scholar
• Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants. 2020;9(1):21.
   Web of Science ®Google Scholar
• Kent PM, Keating JL. The epidemiology of low back pain in primary care. Chiropr Osteopat. 2005;13(1):1–7.
   PubMedGoogle Scholar
• Edwards J, Hayden J, Asbridge M, et al. Prevalence of low back pain in emergency settings: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2017;18(1):1–12.
   PubMedGoogle Scholar
• Phillips CJ. The cost and burden of chronic pain. Rev Pain. 2009;3(1):2–5.
   PubMedGoogle Scholar
• Zis P, Bernali N, Argira E, et al. Effectiveness and impact of capsaicin 8% patch on quality of life in patients with lumbosacral pain: an open-label study. Pain Physician. 2016;19(7):E1049–E1053.
   PubMed Web of Science ®Google Scholar
• Allan GM, Finley CR, Ton J, et al. Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Family Physician. 2018;64(2):e78–e94.
   PubMed Web of Science ®Google Scholar
• Wideman TH, Edwards RR, Walton DM, et al. The multimodal assessment model of pain: a novel framework for further integrating the subjective pain experience within research and practice. Clin J Pain. 2019;35(3):212.
   PubMed Web of Science ®Google Scholar
• Lvovschi VE, Roussel M, Dussart C, et al. Approach to complete the multimodal assessment model of pain. Clin J Pain. 2019;35(7):644–645.
   PubMed Web of Science ®Google Scholar
• Darnall BD, Sturgeon JA, Cook KF, et al. Development and validation of a daily pain catastrophizing scale. J Pain. 2017;18(9):1139–1149.
   PubMed Web of Science ®Google Scholar
• Fritz JM, Irrgang JJ. A comparison of a modified Oswestry low back pain disability questionnaire and the Quebec back pain disability scale. Phys Ther. 2001;81(2):776–788.
   PubMed Web of Science ®Google Scholar
• **Epidiolex SmPC. The European medicinal agency [Online]. Access date 2021 April 05. Available at https://www.ema.europa.eu/en/documents/product-information/epidyolex-epar-product-information_en.pdf
   Google Scholar
• Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020;132(1):56–61.
   PubMed Web of Science ®Google Scholar
• Novotna A, Mares J, Ratcliffe S, et al. A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols*(Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122–1131.
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Rodrigues NP, Silva AL, et al. Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol. 2017;8(259)1-9.
   Google Scholar
• Lewis MA, Russo EB, Smith KM. Pharmacological Foundations of Cannabis Chemovars. Planta Med. 2018;84(4):225–233.
   PubMed Web of Science ®Google Scholar
• Van De Donk T, Niesters M, Kowal MA, et al. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160(4):860–869.
   PubMed Web of Science ®Google Scholar
• Boyaji S, Merkow J, Elman RNM, et al. The role of cannabidiol (CBD) in chronic pain management: an assessment of current evidence. Curr Pain Headache Rep. 2020;24(2):1–6.
   PubMed Web of Science ®Google Scholar
• MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–19.
   PubMedGoogle Scholar
• Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl). 2021 Jan;238(1):9-28. doi: 10.1007/s00213-020-05712-8. Epub 2020 Nov 21.
   Google Scholar
• Crippa JA, Guimarães FS, Campos AC, et al. Translational Investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Front Immunol. 2018;9(2009):1-16.
   PubMedGoogle Scholar